• Fri, Jan. 13, 6:52 AM
    • Johnson & Johnson's (NYSE:JNJ) bid for Actelion (OTCPK:ALIOY) is reportedly in the $250 - 260 per share range, including the proposed spin-out of the R&D organization.
    • Source: StreetInsider
    Fri, Jan. 13, 6:52 AM | 21 Comments
  • Wed, Jan. 11, 4:18 PM
    • According to sources close to the matter, Johnson & Johnson (NYSE:JNJ) has tentatively agreed on an acquisition price for Actelion Ltd. (OTCPK:ALIOY). The negotiations are now focused on valuing the new R&D unit.
    • J&J's most recent bid was $260/share.
    • Source: Bloomberg
    Wed, Jan. 11, 4:18 PM | 24 Comments
  • Fri, Jan. 6, 3:23 AM
    • Complicated takeover? Johnson & Johnson (NYSE:JNJ) and Actelion (OTCPK:ALIOY) have asked Switzerland's takeover board about a deal structure that would separate the latter's commercialized portfolio from its R&D assets, Tages-Anzeiger reports.
    • That would allow J&J to acquire Actelion with a cash offer in the region of $260 per share, a little more than what it had offered when it walked away from negotiations in December.
    Fri, Jan. 6, 3:23 AM | 6 Comments
  • Dec. 29, 2016, 11:07 AM
    • Johnson & Johnson (JNJ +0.3%) is talking about breaking up Actelion (OTCPK:ALIOY) in an acquisition deal, Reuters reports.
    • JNJ had edged out Sanofi from the bidding after entering exclusive talks with the Swiss biotech. Now the negotiations involve separating Actelion's commercialized portfolio from research and development.
    • That would provide for an acquisition in the range of $260/share (slightly more than a previously rejected $250/share) and yet allow Actelion holders to benefit from the R&D pipeline, which would be put into a new publicly traded company.
    Dec. 29, 2016, 11:07 AM | 28 Comments
  • Dec. 22, 2016, 3:42 AM
    • Johnson & Johnson (NYSE:JNJ) has re-entered the race to acquire Actelion (OTCPK:ALIOY) and is now in exclusive talks with the Swiss biotech firm, sidelining Sanofi (NYSE:SNY) from the bidding process.
    • However, Actelion - which has fended off takeover attempts in the past - cautioned that there could be "no assurances" that its talks with J&J would result in a deal.
    • Actelion shares +7.5% in Zurich.
    Dec. 22, 2016, 3:42 AM | 4 Comments
  • Dec. 21, 2016, 11:49 AM
    • Johnson & Johnson (JNJ -0.3%) reports that it is negotiating with Actelion (OTCPK:ALIOY) about a possible transaction, an about-face from its earlier withdrawal after Actelion's apparent rejection of its $250/share bid. Sanofi (SNY +2.2%) is also in the running for the Swiss biopharma firm at ~$275/share.
    Dec. 21, 2016, 11:49 AM | 42 Comments
  • Dec. 5, 2016, 5:04 PM
    • Bloomberg reports that Sanofi (NYSE:SNY) is mulling a bid for Actelion, potentially challenging Johnson & Johnson's (NYSE:JNJ) $250-a-share offer. If so, it will be pricey. Actelion is currently valued at ~$20B.
    Dec. 5, 2016, 5:04 PM | 11 Comments
  • Dec. 5, 2016, 2:53 AM
    • Novartis (NYSE:NVS) CEO Joe Jimenez has played down suggestions the drugmaker could bid for Swiss biotech group Actelion (OTCPK:ALIOY), which is in talks with Johnson & Johnson (NYSE:JNJ) about a transaction.
    • Asked by SonntagsBlick whether Novartis could emerge as a white knight, he said: "We have always said that we will concentrate on complementary acquisitions in the range of $2B-$5B."
    • Actelion is worth nearly $20B at Friday's closing price.
    Dec. 5, 2016, 2:53 AM | 13 Comments
  • Dec. 2, 2016, 4:17 PM
    • Bloomberg reports that, according to sources close to the matter, Johnson & Johnson's (NYSE:JNJ) bid for Actelion (OTCPK:ALIOY) is now north of $250, $4 above its initial offer of $246, which Actelion rejected.
    • According to Mirabaud analyst Nick Turner, the revised bid, a modest 1.6% above the initial price, may get the job done.
    • Previously: Actelion up 16% on higher bid from J&J (Nov. 29)
    Dec. 2, 2016, 4:17 PM | 34 Comments
  • Nov. 29, 2016, 11:02 AM
    • The rollercoaster in the price of Actelion (OTCPK:ALIOY +15.9%) continues. Shares have rebounded sharply from an earlier sell-off in response to the news that suitor Johnson & Johnson (JNJ -0.7%) has raised its offer for the Swiss biotech.
    Nov. 29, 2016, 11:02 AM | 2 Comments
  • Nov. 29, 2016, 6:49 AM
    • Actelion (OTCPK:ALIOY) shares are down almost 6% in Zurich on reports that it is resisting Johnson & Johnson's (NYSE:JNJ) $17B offer for an outright sale. The aim of the complicated deal structure previously reported is to enable the company to remain independent while allowing J&J's U.S. group to retain a major equity stake.
    • Lurking in the background is Sanofi (NYSE:SNY) which could jump into the mix considering its widely-known interest in acquisitions since it plans to divest its generics business. Sanofi shares are up over 1% in Paris.
    Nov. 29, 2016, 6:49 AM | 13 Comments
  • Nov. 29, 2016, 2:50 AM
    • Actelion (OTCPK:ALIOY) is considering a complicated deal to combine with part of Johnson & Johnson (NYSE:JNJ), a move that will leave the Swiss company independent from the U.S. drugs giant, FT reports.
    • The structured transaction would create a new, larger biotech firm uniting Actelion with relevant parts of J&J's pharma business, with the latter becoming a major shareholder in the new business.
    Nov. 29, 2016, 2:50 AM | 2 Comments
  • Nov. 25, 2016, 12:11 PM
    Nov. 25, 2016, 12:11 PM | 22 Comments
  • Nov. 25, 2016, 1:52 AM
    • Johnson & Johnson (NYSE:JNJ) has approached Actelion (OTCPK:ALIOY) about a potential takeover in a bid to boost its pharma business, Bloomberg reports.
    • Europe's largest biotech firm has two pulmonary arterial hyper tension drugs which J&J would love to get its hands on, but deliberations are still at an early stage.
    • Shares in Actelion are up around 13% so far this year, valuing the company at around $17B.
    Nov. 25, 2016, 1:52 AM | 6 Comments
  • Sep. 16, 2016, 3:48 PM
    • Johnson & Johnson (JNJ -0.1%) inks an agreement with Abbott Laboratories (ABT +1.5%) to acquire its Medical Optics unit for $4.325B in cash. The business generated $1.1B in revenues last year in three business segments: cataract surgery, laser refractive surgery and consumer eye health.
    • The deal, expected to close in Q1 2017, will be modestly accretive to JNJ's non-GAAP 2017 earnings.
    Sep. 16, 2016, 3:48 PM | 22 Comments
  • Jun. 21, 2016, 7:54 AM
    • Impax Laboratories (NASDAQ:IPXL) acquires a group of 15 generic drugs from Teva Pharmaceutical Industries (NYSE:TEVA) and affiliates of Allergan (NYSE:AGN) for total consideration of $586M. The transaction also includes the return of the rights to the pending abbreviated New Drug Application (ANDA) for a generic version of Johnson & Johnson's (NYSE:JNJ) Concerta (methylphenidate hydrochloride) to Impax.
    • The deal will be immediately accretive to Impax's earnings. The group generated ~$150M in sales and ~$100M in gross profit in 2015. Per IMS, the U.S. market for the portfolio is ~$3.1B.
    • Impax will finance the acquisition with cash on hand and $400M in term loans.
    • Teva divested the products to satisfy U.S. Federal Trade Commission conditions for its planned acquisition of Allergan's generics business.
    Jun. 21, 2016, 7:54 AM